Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATRN = IMPUNITY.
weak hands getting their shares stolen....
10usd @ end of year...
Regen BioPharma gets positive news on patent application
By Daily Transcript staff report
Wednesday, November 26, 2014
San Diego-based Regen BioPharma Inc. (OTCBB: RGBP) has announced the receipt of a patent for treatment that attacks a gene responsible for the development of stem cell cancers.
Inventors of the intellectual property on which this patent application was filed are University of Toronto hematologist Dr. Richard Wells and Dr. Christine Ichim, a senior research consultant for Regen BioPharma.
The invention is based on findings that leukemic stem cells, which are capable of giving rise to aggressive leukemias, contained high levels of the NR2F6 gene, whereas leukemic cells that are less aggressive and cannot give rise to disease, lack this gene.
When the gene was silenced by a treatment known as shRNA , the stem cells lost leukemia forming ability and turned into normal cells. Subsequently, it was discovered that the same gene target NR2F6 is also found in malignant stem cells in other types of tumors such as breast, lung, ovarian, and colon cancers.
"Dr. Christine Ichim has spent over 10 years in identifying the importance of NR2F6 in cancer stem cells and devising means of killing these tumor-initiating cells by genetically or chemically blocking NR2F6," said David Koos, chairman and CEO of Regen BioPharma, in a statement. "We are enthusiastic about adding this new piece of intellectual property to our developmental pipeline."
Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell field and rapidly advancing these technologies through pre-clinical and Phase 1/2 clinical trials. Currently the company is focused on developing treatments for aplastic anemia, along with gene-silencing therapies for treating cancer.
Weeeeeeee!!
higher highs and higher lows... step by step till 40usd +
Yes... Why???
200???
Lol!! Thanks for the info.
Agreee gooo ;)
Peix 30 usd + .... $$$
http://investors.morningstar.com/ownership/shareholders-overview.html?t=NVAX®ion=usa&culture=en-US
% Owned by institutions.... Wowww
Thanks buddy!! But someone deleted my message... it's info from RGBP.
http://www.marketwired.com/press-release/fda-issues-ind-number-regen-biopharmas-dcellvax-therapeutic-application-proposed-treatment-otcbb-rgbp-1964157.htm
FDA ISSUES IND NUMBER FOR REGEN BIOPHARMA'S dCellVax THERAPUTIC APPLICATION, A PROPOSED TREATMENT FOR BEAST CANCER
Once All of the FDA Comments Are Addressed, the Company Aims to Initiate Gene Silencing Immunotherapy for Metastatic Breast Cancer Patients
SAN DIEGO, CA--(Marketwired - Nov 4, 2014) - Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
Regen's dCellVax therapy is based on US Patent # 8,389,708, acquired from Professor Wei-Ping Min at the University of Western Ontario, Canada, as well as a collaboration between Dr. Min and the Company's Chief Science Officer Dr. Thomas Ichim. Preclinical studies have demonstrated efficacy in mouse models of breast cancer and melanoma.
"We see the granting of an IND number as an important first step in the clinical development of this new personalized therapy that will hopefully add a new treatment option to patients without the horrific side effects of chemotherapies," said Dr. Ichim.
Dr. Ichim further noted, "As part of the clinical trial approval process, we do anticipate comments from the FDA on our application, which will follow a similar pattern to our previous IND application for which a number was issued for our first immunotherapeutic product, HemaXellerate. Once all of the FDA comments are addressed, the Company aims to initiate gene silencing immunotherapy for Metastatic Breast Cancer Patients."
dCellVax is manufactured by generating a potent type of immune system cell, the dendritic cell, from patient's own blood. The dendritic cells are subsequently made resistant to the immune suppressive effects of the tumor by silencing the gene indolamine 2,3 deoxyagenase, technology that was licensed from Benitec BioPharma. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
"I'm extremely excited about the foundation that was laid by Dr. Wei-Ping Min and his academic research leading to our dCellVax therapeutic, along with the accomplishments of Dr. Ichim and his research team in taking the first step in moving dCellVax from an academic concept to a potential drug in development," said David Koos, Chairman & CEO of Regen BioPharma. "While we are beginning with breast cancer, this first trial will serve as validation of our platform, which can be expanded into other tumor types."
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
FDA ISSUES IND NUMBER FOR REGEN BIOPHARMA'S dCellVax THERAPUTIC APPLICATION, A PROPOSED TREATMENT FOR BEAST CANCER
Once All of the FDA Comments Are Addressed, the Company Aims to Initiate Gene Silencing Immunotherapy for Metastatic Breast Cancer Patients
SAN DIEGO, CA--(Marketwired - Nov 4, 2014) - Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
Regen's dCellVax therapy is based on US Patent # 8,389,708, acquired from Professor Wei-Ping Min at the University of Western Ontario, Canada, as well as a collaboration between Dr. Min and the Company's Chief Science Officer Dr. Thomas Ichim. Preclinical studies have demonstrated efficacy in mouse models of breast cancer and melanoma.
"We see the granting of an IND number as an important first step in the clinical development of this new personalized therapy that will hopefully add a new treatment option to patients without the horrific side effects of chemotherapies," said Dr. Ichim.
Dr. Ichim further noted, "As part of the clinical trial approval process, we do anticipate comments from the FDA on our application, which will follow a similar pattern to our previous IND application for which a number was issued for our first immunotherapeutic product, HemaXellerate. Once all of the FDA comments are addressed, the Company aims to initiate gene silencing immunotherapy for Metastatic Breast Cancer Patients."
dCellVax is manufactured by generating a potent type of immune system cell, the dendritic cell, from patient's own blood. The dendritic cells are subsequently made resistant to the immune suppressive effects of the tumor by silencing the gene indolamine 2,3 deoxyagenase, technology that was licensed from Benitec BioPharma. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
"I'm extremely excited about the foundation that was laid by Dr. Wei-Ping Min and his academic research leading to our dCellVax therapeutic, along with the accomplishments of Dr. Ichim and his research team in taking the first step in moving dCellVax from an academic concept to a potential drug in development," said David Koos, Chairman & CEO of Regen BioPharma. "While we are beginning with breast cancer, this first trial will serve as validation of our platform, which can be expanded into other tumor types."
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Agree! ;)
Goooo gooo goooooo
Goooo back to 20 usd... Step by step
;) me too.
Just accumulation... Wait and see...
No problem buddy!!!
In accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, which expires on January 12, 2015 (the "Compliance Period"), to regain compliance with the "Minimum Bid Price Rule"), by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period. If the Company does not regain compliance by January 12, 2015, NASDAQ will provide written notification to the Company that its common stock may be delisted. The Company may, however, be eligible for an additional grace period of 180 calendar days if it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing standards (with the exception of the Bid Price Rule) for listing on The NASDAQ Capital Market, and submits a timely notification to NASDAQ of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split of the shares of its Common Stock, if necessary
Link please.
Goooo
Goooo
Nice buy!!
Agree!
Buying more!!
Long and strong! You will see...
Booommmm....
GAITHERSBURG, Md., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' H7N9 Virus-Like Particle Vaccine Candidate (H7N9 VLP) adjuvanted with Matrix-M(TM). The H7N9 VLP is being developed under the company's contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) (Contract No. HHSO100201100012C) for the development of Novavax' recombinant vaccines to address seasonal influenza and influenza strains with pandemic potential.
"The FDA's Fast Track Designation for our H7N9 VLP underscores the FDA's recognition of the risk of H7N9 influenza, the lack of any approved vaccines for H7N9 influenza, and the strength of our H7N9 VLP," said Stanley C. Erck, President and CEO of Novavax. "This achievement is another example of the capabilities of our technology platform, the commitment of our people, and the importance of our collaboration with BARDA."
In November 2013, Novavax published the first clinical data for any H7N9 Influenza vaccine candidate in The New England Journal of Medicine, which reported positive Phase 1 clinical data from its H7N9 VLP (adjuvanted with a saponin-based adjuvant), in 284 adult subjects, within 180 days of initiating its H7N9 VLP program, an unprecedented achievement in the vaccine industry. The data from this Phase 1 study, along with the positive data released in September 2014 from a Phase 2 trial of 610 subjects, establish Novavax' H7N9 VLP as a leading H7N9 vaccine candidate under development in the industry today.
The Fast Track Drug Development Program was established under the FDA Modernization Act of 1997. A Fast Track designation is intended for products that treat serious or life-threatening disease Less
0,21 AH
Go FREE$$
Click on continue to the page.
Shares in strong hands.... Look the volume...
Lowwwww volume rgbp/bman.... Playing with the low float... A ton of shares in strong hands... No problem... I'm here for a big reward $$$$$$
Remember.... higher highs higher lows